<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03528577</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_17_08</org_study_id>
    <nct_id>NCT03528577</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)</brief_title>
  <official_title>A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-Period, Four-Sequence, Four-Treatment, Placebo and Active Controlled, Comparative, Multiple-Center, Crossover-Design, Bronchoprovocation Study to Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (Albuterol Sulfate) Inhalation Aerosol, eq 90 mcg Base (Teva Respiratory, LLC) in Subjects With Stable, Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90&#xD;
      mcg base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (albuterol sulfate)&#xD;
      Inhalation Aerosol, eq 90 mcg base (Teva Respiratory, LLC) in Subjects With Stable, Mild&#xD;
      Asthma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2018</start_date>
  <completion_date type="Actual">August 3, 2019</completion_date>
  <primary_completion_date type="Actual">March 11, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic Endpoint Post-dose PC20</measure>
    <time_frame>Approximately 15 minutes after last inhalation of study product</time_frame>
    <description>The primary pharmacodynamic endpoint is the post-dose PC20, which is the provocative concentration of methacholine challenge agent required to reduce the forced expiry volume in one second (FEV1) by 20%, following the administration of different doses of albuterol (or placebo) by inhalation.&#xD;
Primary analysis group -pharmacodynamic population.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albuterol Sulfate Inhalation Aerosol, eq 90 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Albuterol Sulfate Inhalation Aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Albuterol Sulfate Inhalation Aerosol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zero-dose</intervention_name>
    <description>Treatment A</description>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Reference Placebo</arm_group_label>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Test Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg of PROAIR® HFA</intervention_name>
    <description>Treatment B</description>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Reference Placebo</arm_group_label>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Test Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180 mcg of 90 mcg of PROAIR® HFA</intervention_name>
    <description>Treatment C</description>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Reference Placebo</arm_group_label>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Test Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg of albuterol sulfate inhalation aerosol</intervention_name>
    <description>Treatment D</description>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Reference Placebo</arm_group_label>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Test Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or non-pregnant women 18 to 65 years of age.&#xD;
&#xD;
          2. Signed informed consent form that meets all criteria of current Food and Drug&#xD;
             Administration (FDA) regulations.&#xD;
&#xD;
          3. Females of childbearing potential must not be pregnant or lactating (as confirmed by a&#xD;
             negative urine pregnancy test&#xD;
&#xD;
          4. Ability to use inhalation aerosol correctly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically significant finding on physical exam in the opinion of the&#xD;
             Investigator, would compromise subject's safety or data integrity.&#xD;
&#xD;
          2. Employees of the Investigator or research center or their immediate family members.&#xD;
&#xD;
          3. Previous participation in this study.&#xD;
&#xD;
          4. Inability to understand the requirements of the study and the relative information and&#xD;
             are unable or not willing to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC Site 02</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC site 01</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 04</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 06</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 05</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 07</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 08</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 03</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <results_first_submitted>July 18, 2020</results_first_submitted>
  <results_first_submitted_qc>January 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>January 2, 2021</last_update_submitted>
  <last_update_submitted_qc>January 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Procaterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03528577/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03528577/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Treatments were administered according to a four-treatment, four-period, four-sequence design.&#xD;
124 eligible subjects were randomized to each one of the four sequences: ABCD&#xD;
Sequence&#xD;
Sequence 1 : A B C D Sequence 2: D C B A Sequence 3: C A D B Sequence 4: B D A C</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Total</title>
          <description>Treatment A: Zero-dose : Two different Reference Placebo inhalers and two different Test Placebo inhalers&#xD;
Treatment B: 90 mcg of Reference : One Reference inhaler, one Reference Placebo inhaler, and two different Test Placebo inhalers&#xD;
Treatment C: 180 mcg of Reference Two different Reference inhalers and two different Test Placebo inhalers&#xD;
Treatment D: 90 mcg of Test One Test inhaler, one Test Placebo inhaler, and two different Reference Placebo inhalers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Sequence 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126">Per report, 119 completed the trial, and all 119 received Treatment A, B, C and D.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed Spirometry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Restricted medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Sequence 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed Spirometry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Sequence 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed Spirometry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Sequence 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed Spirometry</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Baseline</title>
          <description>Summary of Demographic Data and Baseline Characteristics (Safety Population)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of years patient has suffered from symptoms caused by asthma</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.62" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (Pre-saline)</title>
          <description>FEV1 is Forced Expiratory Volume (flow rate) in 1 second</description>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.20" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (Post-saline)</title>
          <description>FEV1 is Forced Expiratory Volume (flow rate) in 1 second</description>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.23" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PC20 FEV1</title>
          <description>PC20 is Provocative concentration (mg/mL) of methacholine required to reduce FEV1 by 20%&#xD;
FEV1 is Forced Expiratory Volume (flow rate) in 1 second</description>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.95" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamic Endpoint Post-dose PC20</title>
        <description>The primary pharmacodynamic endpoint is the post-dose PC20, which is the provocative concentration of methacholine challenge agent required to reduce the forced expiry volume in one second (FEV1) by 20%, following the administration of different doses of albuterol (or placebo) by inhalation.&#xD;
Primary analysis group -pharmacodynamic population.</description>
        <time_frame>Approximately 15 minutes after last inhalation of study product</time_frame>
        <population>The statistical analysis was performed based on the Dose-Scale approach. This approach was referenced in FDA's draft Guidance on albuterol sulfate metered/inhalation and described in FDA's draft Guidance on Orlistat capsule. The PC20 data from various treatments (such as placebo, 90 mcg Test, 90 mcg Reference and 180 mcg Reference) from different study period was pooled to perform the Dose-Scale model using NONMEM. Therefore, per test arm values were not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Analysis Group</title>
            <description>This group included all randomized subjects who:&#xD;
completed at least 1 of the 4 randomized treatment periods with an evaluable PC20FEV1.&#xD;
were compliant with study treatment dosing procedures.&#xD;
did not use any restricted concomitant medications.&#xD;
did not have any other significant protocol deviations.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Endpoint Post-dose PC20</title>
          <description>The primary pharmacodynamic endpoint is the post-dose PC20, which is the provocative concentration of methacholine challenge agent required to reduce the forced expiry volume in one second (FEV1) by 20%, following the administration of different doses of albuterol (or placebo) by inhalation.&#xD;
Primary analysis group -pharmacodynamic population.</description>
          <population>The statistical analysis was performed based on the Dose-Scale approach. This approach was referenced in FDA's draft Guidance on albuterol sulfate metered/inhalation and described in FDA's draft Guidance on Orlistat capsule. The PC20 data from various treatments (such as placebo, 90 mcg Test, 90 mcg Reference and 180 mcg Reference) from different study period was pooled to perform the Dose-Scale model using NONMEM. Therefore, per test arm values were not reported.</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="52.8" upper_limit="162.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <desc>It is the approximate duration over which adverse event data were collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Zero-dose</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>90 mcg of Reference (PROAIR® HFA)</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>180 mcg of Reference (PROAIR® HFA)</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>90 mcg of Test (Albuterol Sulfate HFA Inhalation Aerosol)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>FEV1/FVC ratio</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>accelerated hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials</name_or_title>
      <organization>SPIL</organization>
      <phone>912266455645</phone>
      <email>clinical.trials@sparcmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

